INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
2.560
-0.170 (-6.23%)
At close: Aug 1, 2025, 4:00 PM
2.600
+0.040 (1.56%)
After-hours: Aug 1, 2025, 7:48 PM EDT
INmune Bio Revenue
INmune Bio had revenue of $50.00K in the quarter ending March 31, 2025, with 257.14% growth. This brings the company's revenue in the last twelve months to $50.00K, down -61.83% year-over-year. In the year 2024, INmune Bio had annual revenue of $14.00K, down -90.97%.
Revenue (ttm)
$50.00K
Revenue Growth
-61.83%
P/S Ratio
1,361.17
Revenue / Employee
$2,273
Employees
22
Market Cap
68.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.00K | -141.00K | -90.97% |
| Dec 31, 2023 | 155.00K | -219.00K | -58.56% |
| Dec 31, 2022 | 374.00K | 193.00K | 106.63% |
| Dec 31, 2021 | 181.00K | 170.00K | 1,545.45% |
| Dec 31, 2020 | 11.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
INMB News
- 2 days ago - INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th - GlobeNewsWire
- 4 days ago - INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference - GlobeNewsWire
- 4 weeks ago - INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's - Seeking Alpha
- 4 weeks ago - 'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - Benzinga
- 4 weeks ago - INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 weeks ago - Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain - Benzinga
- 4 weeks ago - INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study - Reuters
- 4 weeks ago - INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease - GlobeNewsWire